BETA
Your AI-Trained Oncology Knowledge Connection!
Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy
David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.
No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease
Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.
Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer
Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.
Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC
The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.
Perioperative Chemo Improves Survival, Control in Esophageal Cancer
Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.
CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC
Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.
Potential Biomarker May Predict Outcomes/Response in RCC
A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.
Casdatifan +/- Cabozantinib Showed Early Efficacy, Safety in Pretreated RCC
Patients with RCC who received 100 mg once daily casdatifan had an ORR of 33%, and those who received casdatifan plus cabozantinib had an ORR of 46%.
Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCC
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC
Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.
Metastasis-Directed RT Without Systemic Therapy Improved Efficacy in RCC
Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC
Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.
Real-World Lurbinectedin Exhibits Safety and Modest Efficacy in ES-SCLC
The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup with a chemotherapy-free interval of 90 or more days.
Dissecting T-DXd/Dato-DXd Approvals in Breast Cancer
With the recent approvals of T-DXd and Dato-DXd, the care for breast cancer continues to evolve and expand.
ODAC Votes Against 2 Belantamab Mafodotin Combinations in Multiple Myeloma
ODAC voted against the favorability of the agent in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma.
FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC
Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.
Nadunolimab Combo Exhibits Early Efficacy in Advanced NSCLC
Particularly strong efficacy signals were observed in patients with non-squamous non–small cell lung cancer previously treated with PD-1 inhibition.
Strategizing ADC Use to Enhance Breast Cancer Outcomes
Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.
Analyzing Emerging Therapies Across Breast Cancer Subtypes
Erika Hamilton, MD, gave an overview of evolving therapies and recent trial updates for patients across breast cancer subtypes.
Assessing ADC Combinations for Treatment in Breast Cancer
Combining ADCs has shown a potential improvement in survival, but it may also come with increased toxicities.
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC
No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.
Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC
Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.
Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial
The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.
ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma
Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.
Finding the Best Sequencing Options for ADCs Across Breast Cancer Subtypes
Cross-resistance makes it important to determine sequencing options across antibody-drug conjugates for patients with breast cancer.
Navigating Treatment Decision-Making for CDK4/6 Inhibitors in Breast Cancer
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
